BioNTech Operating Metrics

Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.

BioNTech key operating metrics including Phase I (Infectious Disease) , environmental, and social and governance score (ESG).

Phase I (Infectious Disease)

40.0%

FY, 2023

Pre-Clinical Phase (Infectious Disease)

50.0%

FY, 2022

Phase II (Oncology)

33.3%

FY, 2023

Operating Metrics

Metrics	FY, 2021	FY, 2022	FY, 2023
Phase I (Infectious Disease)	1	5	3
Pre-Clinical Phase (Infectious Disease)	8	4
Phase II (Oncology)	5	6	8
Pre-Clinical Phase (Oncology)	4	2
Phase I (Oncology)	13	19	7
Commercial Phase (Infectious Disease)	1	2	1
Phase II (Infectious Disease)		1	1
Phase III (Infectious Disease)		1	2
Phase I/II (Infectious Disease)			3
Phase I/II (Oncology)			11
Phase III (Oncology)			2

50-59 out of 100

Community

Employees

Environment

Governance

Premium Content only available in Craft’s Intelligence Portal

Source:CSRHub